Position Title
Associate Professor
- Chemical Engineering
Antibody therapeutics, Protein Engineering, Cancer Immunotherapy, Dual-Specificity antibodies, Cancer Cell Death
Dr. Tushir-Singh’s research focuses on using protein engineering and multi-targeting antibodies in the context of human cancers and other pathologies. He is particularly interested in targeting the differential clinical response of immunotherapies and chimeric-antigen receptor (CAR) cells in solid vs. liquid tumors. Using natural ligands and clinically tested antibodies, he has recently focused on unraveling the unusual apoptotic regulatory motifs, and immunomodulatory cancer signaling pathways downstream of solid tumor enriched death receptor-5 (DR5). For testing hypothesis-driven tumor therapeutics approaches, he extensively uses ovarian and triple-negative breast cancer (TNBC) models in the lab. He is also eager and interested in dual-specificity CAR targeting approaches in ovarian and TNBC models along with SARS-CoV-2 spike processing (S0-S1/S2) inhibition strategies in viral-producing cells.